Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Elbasvir

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Elbasvir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP10

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis69.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Elbasvir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Elbasvir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel

    NCT03144440 · start 2016-12-13

    Registered record
    Registry ID
    NCT03144440
    Conditions
    Hepatitis C
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-12-13
    Completion
    2021-01-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

    NCT02940496 · start 2016-12-09

    Registered record
    Registry ID
    NCT02940496
    Conditions
    BCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Hepatitis C Infection; Refractory Liver Carcinoma; Stage III Hepatocellular Carcinoma AJCC v7; Stage IIIA Hepatocellular Carcinoma AJCC v7; Stage IIIB Hepatocellular Carcinoma AJCC v7; Stage IIIC Hepatocellular Carcinoma AJCC v7; Stage IV Hepatocellular Carcinoma AJCC v7; Stage IVA Hepatocellular Carcinoma AJCC v7; Stage IVB Hepatocellular Carcinoma AJCC v7
    Interventions
    Elbasvir/Grazoprevir; Laboratory Biomarker Analysis; Pembrolizumab; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-12-09
    Completion
    2023-08-09
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBCLC Stage B Hepatocellular Carcinoma; BCLC Stage C Hepatocellular Carcinoma; Hepatitis C Infection; Refractory Liver Carcinoma +7 more
    InterventionElbasvir/Grazoprevir; Laboratory Biomarker Analysis; Pembrolizumab; Ribavirin
    PhasePhase 2
    Registry statusCompleted

  • Portal-724 MEMS for Medication Adherence Patients Taking HCV Medications

    NCT02858050 · start 2016-09-09

    Registered record
    Registry ID
    NCT02858050
    Conditions
    Adherence
    Interventions
    Portal-724 MEMs Cap
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-09-09
    Completion
    2018-01-25
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdherence
    InterventionPortal-724 MEMs Cap
    PhaseNot recorded
    Registry statusCompleted

  • Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

    NCT02890719 · start 2016-08-03

    Registered record
    Registry ID
    NCT02890719
    Conditions
    Liver Transplantation; Hepatitis C
    Interventions
    Grazoprevir 100 mg/day; Elbasvir 50 mg/d; Grazoprevir 100 mg/day; Elbasvir 50 mg/day; Ribavirin 1200 mg/day
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2016-08-03
    Completion
    2017-06-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation; Hepatitis C
    InterventionGrazoprevir 100 mg/day; Elbasvir 50 mg/d; Grazoprevir 100 mg/day; Elbasvir 50 mg/day +1 more
    PhasePhase 3
    Registry statusWithdrawn

  • Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis

    NCT02732405 · start 2016-05

    Registered record
    Registry ID
    NCT02732405
    Conditions
    Hepatitis C; Compensated Cirrhosis
    Interventions
    MK5172 /MK8742
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-05
    Completion
    2017-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Compensated Cirrhosis
    InterventionMK5172 /MK8742
    PhasePhase 3
    Registry statusUnknown

  • Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

    NCT02647632 · start 2016-01

    Registered record
    Registry ID
    NCT02647632
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir/Elbasvir; Sofosbuvir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-01
    Completion
    2017-04
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir/Elbasvir; Sofosbuvir; Ribavirin
    PhasePhase 2
    Registry statusCompleted

  • Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

    NCT02251990 · start 2015-01-28

    Registered record
    Registry ID
    NCT02251990
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir/Elbasvir; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-01-28
    Completion
    2017-04-10
    Enrolment
    489

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir/Elbasvir; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)

    NCT02332720 · start 2015-01-28

    Registered record
    Registry ID
    NCT02332720
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir; Uprifosbuvir; Elbasvir; Ruzasvir; MK-3682B; Ribavirin (RBV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01-28
    Completion
    2017-05-03
    Enrolment
    413

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir; Uprifosbuvir; Elbasvir; Ruzasvir +2 more
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)

    NCT02332707 · start 2015-01-22

    Registered record
    Registry ID
    NCT02332707
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir; Uprifosbuvir; Elbasvir; Ruzasvir; Uprifosbuvir (+) Grazoprevir (+) Ruzasvir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01-22
    Completion
    2016-12-06
    Enrolment
    443

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir; Uprifosbuvir; Elbasvir; Ruzasvir +2 more
    PhasePhase 2
    Registry statusCompleted

  • HCV Treatment in a Low-threshold Clinic

    NCT04063839 · start 2015-01

    Registered record
    Registry ID
    NCT04063839
    Conditions
    Hepatitis C; Substance Use Disorders
    Interventions
    Elbasvir / Grazoprevir Oral Tablet
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2022-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; Substance Use Disorders
    InterventionElbasvir / Grazoprevir Oral Tablet
    PhaseNot recorded
    Registry statusUnknown

  • Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)

    NCT02252016 · start 2014-10-22

    Registered record
    Registry ID
    NCT02252016
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir + Elbasvir; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10-22
    Completion
    2016-06-14
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir + Elbasvir; Placebo
    PhasePhase 3
    Registry statusCompleted

  • An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)

    NCT02105688 · start 2014-09-02

    Registered record
    Registry ID
    NCT02105688
    Conditions
    Chronic Hepatitis C
    Interventions
    Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A); Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-09-02
    Completion
    2018-12-04
    Enrolment
    301

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionGrazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A); Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet
    PhasePhase 3
    Registry statusCompleted

  • Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)

    NCT02105467 · start 2014-06-05

    Registered record
    Registry ID
    NCT02105467
    Conditions
    Chronic Hepatitis C Virus
    Interventions
    Grazoprevir 100mg / Elbasvir 50 mg FDC; Placebo to Grazoprevir / Elbasvir 50 mg FDC
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-06-05
    Completion
    2015-09-06
    Enrolment
    421

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C Virus
    InterventionGrazoprevir 100mg / Elbasvir 50 mg FDC; Placebo to Grazoprevir / Elbasvir 50 mg FDC
    PhasePhase 3
    Registry statusCompleted

  • Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

    NCT02105701 · start 2014-06-05

    Registered record
    Registry ID
    NCT02105701
    Conditions
    Hepatitis C Infection
    Interventions
    Grazoprevir + Elbasvir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-06-05
    Completion
    2015-06-19
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Infection
    InterventionGrazoprevir + Elbasvir; Ribavirin
    PhasePhase 3
    Registry statusCompleted

  • An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)

    NCT02105662 · start 2014-06-03

    Registered record
    Registry ID
    NCT02105662
    Conditions
    Chronic Hepatitis C
    Interventions
    Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-06-03
    Completion
    2015-05-22
    Enrolment
    218

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionGrazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets
    PhasePhase 3
    Registry statusCompleted